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Background: Inhibitors of Apoptosis (IAP) family play a critical role in apoptosis and inflammatory response.
Neuronal Apoptosis Inhibitory Protein (NAIP), as a member of both IAPs and NLR families (NOD-Like Receptor), is a
unique IAP harboring NOD (Nucleotide Oligomerization Domain) and LLR (Leucine Rich Repeat) motifs. Considering
these motifs in NAIP, it has been suggested that the main function of NAIP is distinct from other members of IAPs.
As a member of NLR, NAIP mediates the assembly of ‘Inflammasome’ for inflammatory caspase activation.
Pathologic expression of NAIP has been reported not only in some infectious and inflammatory diseases but also
in some malignancies. However, there is no report to elucidate NAIP expression in lymphomatic malignancies.
Methods: In this study, we examined NAIP protein expression in 101 Formalin-Fixed Paraffin-Embedded blocks
including samples from 39 Hodgkin Lymphoma and 23 Non Hodgkin Lymphoma cases in comparison with 39
control samples (30 normal and 9 Reactive Lymphoid Hyperplasia (RLH) lymph nodes) using semi-quantitative
immuno-flourecent Staining.
Results: NAIP expression was not statistically different in lymphoma samples neither in HL nor in NHL cases
comparing to normal samples. However, we evaluated NAIP expression in normal and RLH lymph nodes.
Surprisingly, we have found a statistically significant-difference between the NAIP expression in RLH (M.R of NAIP/
GAPDH expression = 0.6365 ± 0.017) and normal lymph node samples (M.R of NAIP/GAPDH expression = 0.5882 ±
0.047) (P < 0.01).
Conclusions: These findings show that the regulation of apoptosis could not be the main function of NAIP in the
cell, so the pathologic expression of NAIP is not involved in lymphoma. But, we concluded that the over
expression of NAIP has more effective role in the inflammatory response. Also, this study clarifies the NAIP
expression level in lymphoma which is required for IAPs profiling in order to be used in potential translational
applications of IAPs.
Keywords: Inhibitor of apoptosis protein, NAIP/BIRC1, Inflammatory caspases, Inflammasome, Hodgkin lymphoma,
Non-Hodgkin lymphoma, Semi-quantitative immuno-flourecent staining
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Apoptosis is a programmed process leading to cell death
which controls the development and homeostasis of mul-
ticellular organisms [1]. This cell destruction executes
when initiator caspases are assemble with adaptor mole-
cules in response to internal or external signal, leading to
caspase activation [2-4]. Up to now, numerous literatures
have been reported on critical role of apoptosis in differ-
ent pathological conditions [5]. The loss of apoptosis reg-
ulation might proceed in a wide variety of diseases like
cancer development and progression while the excess of
apoptosis might result in neurodegenerative [6] and
immunodeficiency disorders [1]. So, the impaired regula-
tion of apoptosis is considered to be a prominent event
in the development and progression of tumor cells [7,8].
The mechanisms of these defects, however, have not
been fully elucidated. But, a complex network of pro-
and anti-apoptotic proteins governing the tight regula-
tion of apoptosis has been revealed [1]. Among anti-
apoptotic proteins, a group of structurally related pro-
teins, known as the inhibitor of apoptosis proteins (IAPs)
are the only cellular factors that act both as the initiator
and effector caspases [1,5,9].
IAPs family plays critical role in apoptosis and inflam-
matory process and as its name implies, it can inhibit
the apoptosis induced by a variety of stimuli. Therefore,
the over expression of various IAPs is regarded as an
unfavorable feature at diagnosis and poor treatment
response [8,10-12].
Structurally, IAP family proteins are characterized by
t h ep r e s e n c eo fo n eo rat a n d e mr e p e a to ft h r e eB I R
domains [2]. The BIR domain is a zinc-binding fold of
approximately 70 invariant amino acids [13,14], includ-
ing three conserved cysteine and one conserved histidine
residues within the sequences CX2CX16HX6-8 C[ 1 5 ] .
What is important about BIR domain is that This
domain has a critical role for the anti-apoptotic proper-
ties of the IAPs [2] which the interaction between a
functional BIR domain and IAP-binding motifs (IBMs)
of executioner caspase-3 and -7 as well as initiator cas-
pase-9 [2,13] leads to the apoptosis regulation by IAPs
protein.
In general, IAPs are involved in apoptosis regulation
through interaction between its functional BIR domain
and IAP-binding motifs (IBMs) of executioner caspase-3
and -7 as well as initiator caspase-9 [2,13]. In addition
to BIR domain, IAPs harbor other kind of domains like
RING, CARD and NOD. The presence of these domains
make it possible that beside the apoptosis inhibition,
IAPs participate in other accessory biological functions
like cell development and differentiation, cell cycle pro-
gression, cell division, cell signal transduction, cell pro-
liferation, cell motility and also the most important one,
immune responses [2,16,17].
Up to now, as many as eight human IAP members have
been identified, NAIP/BIRC1, cIAP-1/BIRC2, cIAP-2/
BIRC3, XIAP/BIRC4, SURVIVIN/BIRC5, BRUCE/BIRC6,
ILP-2/BIRC8 and Livin/BIRC7 [13,16]. Based on the pre-
s e n c eo ra b s e n c eo faR I N Gf i n g e ra n dt h eh o m o l o g yo f
their BIR domain, this protein family has been divided
into 3 classes of 1, 2 and 3. Class 1 IAPs (XIAP, cIAP-1,
cIAP-2, ILP-2 and Livin) contains homologous BIR
domains and a RING finger motif. Class 2 IAPs (NAIP)
has three BIR domains but no RING finger motif. Not to
mention that class 2 BIR domains are more distantly
related to the BIR domains of the class 1 IAPs. And class
3 IAPs (SURVIVIN and BRUCE) contain only a single
BIR domain and no RING finger [16,18].
The evaluated IAP in this study, Neural Apoptosis Inhi-
bitory Protein (NAIP) was identified in 1995 by Roy et al.,
while they were searching for a gene on chromosome
5q13 responsible for childhood muscular atrophy [16].
Later, it was also detected that NAIP is associated to the
inherited disease, spinal muscular dystrophy (SMA), which
occurs in childhood and manifests as a degeneration of
motor neurons [19]. In this case, Mutations which loss the
NAIP functions lead to dys-regulation of apoptosis in
lower motor neurons. Consistent with this phenotype,
NAIP appears to be mainly expressed in neurons where its
role is to protect cells against apoptosis [20] and it plays a
crucial role for survival of neurons in the pathological con-
dition [15,17].
The NAIP/BIRC1 gene coding region spans 4,212
nucleotides encoding 1403-amino acids of the 156 kDa
protein. This sole member of class 2 IAPs protein (NAIP)
contains 3 sequential BIR domains at N-terminus. In addi-
tion to the BIR domain, NAIP carries a NOD followed by
a LRR [4,17]. So, it is obvious that BICR1/NAIP would be
quite typical among other IAPs. So It has been suggested
that NAIP functions are distinct from other IAP proteins
by harboring NOD and LRR domains [2].
Thanks to presence of NOD domain and LRR motif in
NAIP protein, it belongs to not only the IAPs protein
family but also the NLR protein family. NOD domain in
the NAIP is essential for for the oligomerization of the
molecules involving in signal transduction and also LRR
domain involves for senseing microbial motif. In human,
NLRs protein family is composed of 23 members which all
of them are intercellular sensors that have key role in
innate immunity and inflammation [21,22]. NAIP along
with some other members of NLR such as NALPs and
IPAF promote the assembly and regulation of cytoplasmic
multiprotein complex termed “inflammasome”. This pro-
tein complex is required for the activation of inflammatory
caspases (group I caspase) in response to several stimuli
[21,23,24].
The inflammatory caspases in human consist of cas-
pase 1, 4, 5, 11 and 12. The best characterized one,
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involves in cytokine maturation such as pro-IL1 b,p r o -
IL18 and possibly Pro-IL33. These cytokines are mostly
involved in the innate immunity [21,23,25].
Taking into account the possible role of NAIP as a
modulator in assembling of inflammasome for inflam-
matory caspase activation [20], it might be suggested
that the main function of NAIP in the cell is involve-
ment in the inflammatory process not in the apoptosis
inhibition. On the other word, the pathologic expression
of NAIP might be involved in the infectious [22] and
inflammatory diseases [20] not in the malignancies.
T h e r ea r eaf e ws t u d i e so nt h ep o t e n t i a lr o l eo fN A I P
over expression in apoptosis regulation and its clinical
relevance in tumor context. So far, high level expression
of NAIP has been reported in prostate cancer cell line
[1,26], breast cancer patients [10] and bone marrow of
A M L[ 8 ] .B u t ,t h e r ei sn or e p o r to nt h ep o s s i b l er o l eo f
NAIP in lymphoma malignancies.
Taking together, NAIP has two different biologic func-
tions in the cells, one in inflammatory process through
the inflammatory caspase-1,-4 and -5 activation [23] and
other in apoptosis regulation via the executioner cas-
pase-3 and -7 inhibition [1].
In general, HL is characterized by favorable prognosis
in clinical setting and by a heterogenous cellularity,
comprising a majority of inflammatory non-neoplastic
cells as well as a minority of specific neoplastic cells
[27-29]. NHL is classified into low grade and high grade
lymphomas [30-32]. In this study, the lymphoma group
consisted of 39 HL and 23 NHLs. we considered the
available FL cases as a representative of other low grade
NHLs as well as the available DLBCL and ALCL cases
as a representative of other high grade NHLs, hoping to
better understanding about main function of NAIP in
Lymphoma context by evaluating the NAIP protein
expression.
So, considering the possible bi-functional activity of
NAIP in cells, we aimed to evaluate the NAIP expression
differences in the malignant lymph nodes in comparison
with non-malignant ones. And we also compared the
expression of NAIP between normal lymph node samples
and follicular hyperplasia lymph node samples due to the
possible function of NAIP in inflammatory response
We aimed to evaluate the differences of NAIP expres-
sion in the malignant lymph nodes comparing to in the
non-malignant lymph nodes, and we also compare.
Materials and methods
Ethics committee approval
The study was performed on human lymph node sam-
ples with the approval of the Ethics Committee of the
Deputy for Research of Isfahan University of Medical
Sciences.
Patient and donor material
In this study, we use evaluated 101 paraffin embed block
including 39 and 23 FFPE-tissue blocks which were
d i a g n o s e da sH La n dN H Lr e s p e c t i v e l yc o n s i d e r e da sa
subject group. The NHL case group consisted of 6, 15
and 2 cases of FL, DLBCL and ALCL respectively.
Furthermore, 30 FFPE-tissue blocks of normal and 9
FFPE-tissue blocks of RLH nodes were used as the con-
trol group.
The lymph nodes were excised in the department of
surgery, University Hospital of St. Seyed Alshohada and
St. Al’Zahra, Isfahan University of Medical Sciences,
from 2006 to 2010.
The Primary diagnosis for HL and NHL was per-
formed based on histological examination through H&E
staining and immunophenotype examination of CD15/
Leu-M1, CD30, CD19, CD20, CD22, CD45/LCA and
CD79 diagnostic marker panel by IHC. Those finally eli-
gible lymph node blocks for this study were confirmed
again by hematopathologist with supplementary immu-
nohistochemical staining (detailed data not given).
Clinical features of all patient including sex, age, B-
symptom (fever, night sweats, weight loss), lymph node
involvement site (cervical, auxiliary, mediastinum, para
aortic, parahilar, inguinal) and extra-lymphatic organ
involvement(lung, liver, spleen, bone marrow)were
recorded and clinical staging based on Ann Arbor criteria
was performed by oncologist.
Immunostaining
The samples were subjected to paraffin wax histology
using standard method. Histological sections (3 μm)
were cut using a Jung rotary microtome, floated out on
a 50-50 volume mixture of absolute ethanol-distilled
water at 48°C, and then mounted on glass microscope
slides, which were previously coated with 3-aminopro-
pyltriethoxysilane prior to overnight storage at 37°C.
The applied semi-quantitative method in this study
was the same as method that was developed and applied
by our lab in previous studies with minor modification
[33]. Briefly, to measure NAIP expression in all cases,
NAIP expression needs to be assessed by comparison
between this protein (NAIP) and a house keeping pro-
tein (GAPDH).
To do that, we used two antibodies against NAIP and
GAPDH. Because the expression of GAPDH is constant
in normal and neoplastic lymphoid tissue, any differ-
ences in NAIP/GAPDH ratio indicate changes in NAIP
protein expression. This is a semi-quantitative method
to compare protein expression in tissue sections.
N A I Pa n dG A P D Hp r o t e i ne x p r e s s i o nw e r em e a s u r e
using semi-quantitative immunofluorescent assay. For
NAIP detection, we used NAIP primary antibody Bacu-
loviral IAP Repeat -containing (BIRC1/NAIP) Rabbit
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GAPDH primary antibody was Glyceraldehyde 3-Phos-
phate Dehydrogenase (GAPDH) mouse anti-Human IgG
monoclonal (2D4A7) antibody (Lot ID:LS-B520). These
antibodies were purchased from Life Span Biosciences
Company(USA). Fluorochrome-conjucated secondary
antibody against NAIP and GAPDH were Fluorescein
(FITC) Affini Pure Goat anti-rabbit IgG (H + L) and
Texas Red Affini Pure Goat anti- mouse IgG (H + L),
respectively. These reagents were purchased from Jack-
son immune Company (USA).
Slide preparation involves transferring sections to
slides, removal of paraffin, re-hydration and also antigen
retrieval treatment. Sections were de-paraffinized
through microwave oven (67°C for 45 min) and Xylene
treatment (4 × 10 min). Then, they were gradually rehy-
drated in the following manner:75% Alcohol (1 × 5 min),
85% Alcohol (1 × 5 min), 95% Alcohol (1 × 5 min) and
finally absolute Alcohol (2 × 5 min), deionised water (5
min), Phosphate buffer saline (PBS)(2 × 5 min).
After re-hydration, slides were allowed to dry at room
temperature, and then with DAKO Pen, the rim of tissue
section on slides was marked. Next, 150 μlo fP B Sw a s
added to each slides and incubated for 15 min at 37°C in a
humidified chamber before antibody treatment. Primary
antibodies (NAIP and GAPDH) were diluted to its optimal
dilution (1/100) in diluents. After that, 50 μlo ft h ep r i -
mary antibodies were added to the slides and incubated
for 45 min at 37°C before rinsing slides with PBS. The fol-
lowing steps need to be done in dark.
The secondary conjugated antibodies were diluted to
their optimal dilution (1/50) in diluents. Then, 50 μlo f
secondary antibodies were applied to each slides, The
slides were then incubated for 1 h at 37°C, before washing
in PBS (2 × 10 min).
In this study NAIP was stained with FITC and
GAPDH was stained with Texas Red conjugation.
Finally, all slides covered with cover slip, sealed with
clear nail polish and kept in a cold and dark place.
Image analysis
Prepared slides were examined using a LEICA fluores-
c e n c em i c r o s c o p e( B Z 0 0 )w i t hf i l t e rs e t ss u i t a b l ef o r
FITC & Texas Red dyes. Two images were taken from
each microscope field, one with blue filter (350-450 nm)
and another with green filter (550-650 nm).
Furthermore, for each sample, between 20 and 30
images were taken from different sites of the tissue sec-
tion, randomly. The images were transferred to computer
monitor and saved. Images were captured using a cooled
charge coupled device (CCD) camera (LEICA: DC 350F)
interfaced with a PC computer. We analyzed these saved
images by using an image processing algorithm in
MATLAB.7 software.http://www.mathworks.com. Whole
boundary of desired cells in both green and red plane of
our available images were selected and then the ratio for
intensity between the mean of pixels in green and red
plane of selected cells was computed by following ratio
formula:
Ratio=
Mean of pixels intensity for a cell in green plane(indicated NAIP expression)
Mean of pixels intensity for the same cell in red plane (indicated GAPDH expression)
Unlike some previous studies, which were selected &
analyzed images randomly among all samples In this
study [34], in order to acquire a high accurate and trust-
worthy results, samples were analyzed one to one. Of all
taken images for each sample, a 30-cell- collection was
selected and then analyzed by the above software. The
total cell count was more than 3,000 cells in all pre-
pared HL, NHL and the control sections.
For the HL cases, the desired cells for analyzing were
preferentially lymphocytes in the heterogeneous back-
ground population. In contrast to NHL which contains
a homogeneous population of malignant cells, the
desired cell selection for the HL samples was challenge-
able and time-consuming.
Statistical analysis
One way analysis of variance (ANOVA) and student’s
t-test were run to analysis the mean level of NAIP
expression ratio between both cases (HL and NHL) and
control groups. Furthermore, c
2 and Fisher’se x a c tt e s t s
were applied to analysis data in clinical features’ part of
the study. Table 1.
Results
In this study, the expression profiling of NAIP in 39 HL
was compared to 39 non-neoplastic lymphoid tissues
(30 normal and 9 RLH lymph nodes). As well as, NAIP
protein expression in the 23 low and high grade NHLs
was compared with the control group. The NAIP pro-
tein expression was measured in all samples. To fulfill
this purpose, multi-color FISH method was modified
and applied for semi-quantitative Immunoflourecent.
This procedure had been developed to detect expression
of more than one protein within the same cell, at the
same time. In fact, the quantitative evaluation of any
intended protein expression would be achievable just by
considering the relative hybridization signal intensities
from two different proteins. One with a variable expres-
sion and another with constant expression termed
housekeeping gene in neoplastic and normal lymphoid
tissue. This method was developed by our lab in pre-
vious studies. It provides acceptable data for measure-
ment of protein expression within the context of any
individual cell. We calculated alteration in the expres-
sion of NAIP protein in our samples based on decrease
or increase NAIP/GAPDH ratio. Any changes in the
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(conjugated hybrid with GAPDH) indicate changes in
the expression of NAIP. Figure 1.
To determine whether or not NAIP up-regulation
occurs in neoplastic tissue, around 1,030 infiltrating cells
in all HL samples (mostly lymphocyte) and approximately
the same number of background cells in both normal and
RLH lymph nodes were analyzed. M.R of NAIP/GAPDH
expression in all HL cases was 0.5834 ± 0.021 and in con-
trol group was 0.5987 ± 0.045. So, NAIP expression was
not statistically significant between HL and control group
samples (P = 0.07, t-test). Figure 2.
Table 1 Clinical features of patient with hodgkin lymphoma(HL)
Clinical features of patient with HL






B symptom HL 14 17
NHL 11 10
1- Fever HL 9 out of 14 NHL 7 out of 11
2-night sweat 7 out of 14 6 out of 11




HL 26 5 9 3 3 4
NHL 12 4 3 0 3 2
extra-lymphatic organ involvement Lung liver spleen bone marrow others
HL 32 3 0 4
NHL 31 2 0 1
   A.                                                                       .B 
Figure 1 Representative of the NAIP and GAPDH expression detected by FITC and Texas Red conjugated antibodies, respectively. (A)
And (B) are images of HL.
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in NHLs. To do those approximately 800 malignant
cells in three types of NHLs were measured. Then, the
acquired results between NHLs and control cases were
analyzed. The M.R of NAIP/GAPDH expression in all
t y p e so fN H Lw a s0 . 6 0 4 0±0 . 0 2 6a n di nc o n t r o lg r o u p
was0.5987 ± 0.045. The result shows that over expres-
sion of NAIP between NHLs and control group was not
statistically significant (P = 0.03, t-test). Figure 3.
Then, we subdivided the NHLs case group into low
grade and high grade entities and analyzed again. The M.
R of NAIP expression in FL as a representative of low
grade lymphoma was 0.5886 ± 0.012 while the M.R of
NAIP expression in both DLBCL and ALCL as a repre-
sentative of high grade or aggressive lymphoma was
0.6095 ± 0.028. Despite a slight increase of NAIP expres-
sion in high grade lymphoma comparing to low grade
one, over expression of NAIP was not statistically signifi-
cant neither in low grade nor in high grade NHLs in
compression with the control group. (P = 0.78, P = 0.23,
respectively. t-test). Figure 4.
Moreover, we evaluated NAIP expression separately in
normal and RLH lymph nodes. Surprisingly, there was
found a statistical difference between the NAIP expres-
sion in RLH (M.R of NAIP/GAPDH expression =
0.6365 ± 0.017) and the same number of normal lymph
nodes (M.R of NAIP/GAPDH expression = 0.5882 ±
0.047) (p > 0.05). Figure 5.
Indeed, our study did not reveal any correlation
between the level of the NAIP expression and the prog-
nostic factors such as age, gender, B symptom and lym-
phoid and extra-lymphoid tissues involvements in both
HL and NHL. Clinical features of case group are shown
in Table 1.
Discussion
This study sheds new light on the expression status of
NAIP which can potentially participate in both apopto-
tic and inflammatory processes in human malignancies.
NAIP was identified in 1995 when Roy et al. were
searching for gene on chromosome 5 responsible for
childhood muscular atrophies [15]. Then, mutation in the
NAIP has been linked to development of spinal muscular
atrophy (SMA), which is a progressive motor neurodegen-
erative disorder [19]. Considering NAIP involvement in
SMA, it has been suggested that NAIP is mainly expressed
in neurons and plays a prominent role in survival of neu-
rons due to protection of neurons against apoptosis
[15,17,20]. Although in some studies it has been claimed
that NAIP is a direct inhibitor of caspase-3 and -7 [19] but
in other review it has been reported that the mechanisms
for the antiapoptotic effect of NAIP has not been exactly
elucidated and all of the human IAPs family members,
with exception of NAIP interact with specific cysteine pro-
teases, or caspases, required for the cleavage of certain
proteins involved in the disassembly of the cell during
apoptosis [14].
Up to now, in few studies, the overexpression of NAIP
in malignancies has been validated and considered as an
effective factor for tumor development and progression.
H i g hl e v e le x p r e s s i o no fN A I Pa l o n gw i t hS U R V I V I N ,
cIAP-1, cIAP-2 and XIAP were reported in prostate
cancer cell line [1,26]. Also, NAIP overexpression in
Figure 3 The M.R of NAIP/GAPDH expression in 23 cases of
NHLs and 39 cases of control group. The NAIP protein expression
between these groups was not statistically significant.
Figure 2 The M.R of NAIP/GAPDH expression in 39 cases of HL
and 39 cases of control (normal and RLH) lymph nodes. The
NAIP protein expression in HL and control grope was not
statistically significant.
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cal features was detected using quantitative RT-PCR and
it was suggested that NAIP would play a role in disease
progression [10]. Furthermore, strong expression of
NAIP along with SURVIVIN was observed in the bone
marrow of AML patients [8].
On the other hand, with emphasis on functional
domains (NOD and LRR) of NAIP protein [23], in some
studies, NAIP has been introduced as a regulator for
inflammasome formation, a cytoplasmic protein com-
plex that activates inflammatory caspases in response to
different stimuli [20]. So, regardless of apoptosis inhibi-
tory activity of NAIP, its pathologic expression might be
considered to be involved indirectly in some infectious
[22] and auto-inflammatory diseases [20].
To better understand the controversial function of
NAIP, we decided to evaluate NAIP expresstion in
lymphomas. This is the first study to elucidate the NAIP
expression not only in HL but also in NHLs. We found
that the differences in expression of NAIP are not statisti-
cally significant in none of favorable (HL), low grade (FL)
and even high grade (DLBCL and ALCL) types of lym-
phoma in comparison with non-neoplastic control group.
This result suggests that the regulation of apoptosis might
not be the main function of NAIP unlike other IAPs.
Although Semi-quantitative Immuno-flourecent Stain-
ing and IHC have some advantages in detecting specific
proteins in histological observations [10], but highly sen-
sitive and quantitative analysis such as RT-PCR is recom-
mended for underpinning and guaranteeing this report.
Surprisingly, we found significantly different expres-
sion of NAIP between the RLH lymph nodes and the
same number normal lymph nodes in the control group.
Considering our finding and taking into account the
fact that inflammatory reaction is a cornerstone in RLH
pathogenesis against a long list of bacteria, viruses,
environmental pollution, drugs and altered tissue com-
p o n e n t s[ 2 2 ] ,w ep r o p o s et h a tt h em a i nf u n c t i o no f
NAIP might be in the inflammatory process. But, we
strongly recommend evaluating the NAIP expression in
RLH with larger number of non-neoplastic lymphade-
nophathy subclasses.
Finally, considering the required Pan-IAPs profiling
for translational application of IAPs as an attractive
therapeutic target, prognostic and diagnostic marker
[13,16], we have elucidated the NAIP expression level in
different subtypes of lymphoma.
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